Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials

BACKGROUND: In October 2014, the US Food and Drug Administration released a draft guidance for the development of drugs for the acute treatment of migraine. This guidance offered the option of replacing the previously required 4 co‐primary endpoints: pain freedom, freedom from nausea, freedom from p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hindiyeh, Nada A., Kellerman, Donald J., Schmidt, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Headache Currents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593965/
https://www.ncbi.nlm.nih.gov/pubmed/30953576
http://dx.doi.org/10.1111/head.13511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593965/
https://www.ncbi.nlm.nih.gov/pubmed/30953576
http://dx.doi.org/10.1111/head.13511

Ejemplares similares